Nomi Health

A new KFF analysis (https://lnkd.in/g3Dp3SrJ) revealed that over 40% of privately insured adults under 65 could be eligible for GLP-1 treatments. As GLP-1 medications reshape the healthcare landscape, employers need expert guidance. We’re partnering with Crain's Grand Rapids Business, bringing together a panel of experts — Kevin Venet, Dominick Pallone, Jay Ofield, Danielle Barrieau —?to discuss the impact of GLP-1s on employers. Register now, and we’ll see you next Thursday, Sep. 19, at 1 p.m. ET: https://lnkd.in/gcYsq3js #DataAnalytics #HealthcareData #HealthcareBenefits #EmployeeBenefits

As The Washington Post reports, people are now starting to receive letters from UnitedHealth about the #ChangeHealthcare data breach. (Read more: https://lnkd.in/gtuN7bk5) They're handing out paper umbrellas in a Cat5 hurricane. Our Co-Founder and CTO Boe Hartman says, "UnitedHealth’s response to this monumental breach is not just inadequate; it’s a slap in the face to millions of us whose most sensitive data is now exposed. Their grand gesture: mailing letters to victims (while admitting they don’t even have all the addresses) and offering two years of complimentary credit monitoring and identity theft protection services." Drawing on Nomi's extensive experience in healthcare innovation, Boe outlines in MedCity News what real, effective action should look like in the face of this unprecedented data breach: https://lnkd.in/gWEGdUiA #CreditMonitoring #DataBreach #HealthcareData

Our Trends in Spend analysis reveals the rapid growth of GLP-1 medications for diabetes and weight loss: ?? Now 9% of total drug spend, up from 4% in 2020 ?? Utilization soared 50% annually ?? Weight loss prescriptions jumped from 10% to 24% in one year ?? Costs held steady at $1,100 per prescription These trends emphasize the importance for employers to tackle rising costs and consider the long-term health impacts. Explore our full #GLP1 trends analysis:?https://lnkd.in/ebPTGrDZ #DataAnalytics #HealthcareData #HealthcareBenefits #PrescriptionSpending

This week, we launched a LinkedIn newsletter — Healthcare Rebuild — to share industry insights, grounded in facts and data, with employers and governments that no longer want to be passive buyers, providers who need more support, and informed patients who refuse to be left holding the bag. In the Healthcare Rebuild newsletter, we'll introduce you to bright minds, bold ideas and proven tactics that are flipping healthcare on its head. The tipping point is here. Subscribe now:?https://lnkd.in/dtG7z9xT #Newsletter #HealthcareNewsletter #HealthcareIndustry #HealthcareTransformation

The $4 trillion+ healthcare industry currently goes more unchecked than any other, but we're empowering buyers of care to join us in rebuilding healthcare. In the Healthcare Rebuild newsletter, we'll introduce you to bright minds, bold ideas and proven tactics that flip healthcare on its head to make it work like a true system —?a system that no longer favors complexity over transparency. One that prioritizes patients over profit. Please subscribe to Healthcare Rebuild for more insights grounded in facts and data, directly from Nomi Health to you. #Healthcare #HealthcareFinance #HealthcareBenefits #HealthcareCosts #HealthcareInnovation

GLP-1 medications offer promising weight loss results, but come with complex considerations: ?? Long-term efficacy uncertainties ?? Ongoing safety monitoring needs ?? Persistent supply shortages ?? Off-label usage concerns ?? High costs averaging $936 per prescription We understand employers must navigate these challenges while supporting employee health. Learn more about how to develop a GLP-1 strategy for your business:?https://lnkd.in/gR4fgZKc #EmployeeBenefits #HealthcareBenefits #PrescriptionCosts #GLP1s

I'll be leading a discussion for Crain's Grand Rapids Business Content Studio and our partners at Nomi Health on the impact of GLP-1 drugs: "GLP-1s: The $100 billion question for your business." With projections hitting $100 billion in annual sales by 2030, these medications are set to become the most expensive drug class in history. Can your business afford to ignore their impact? We have a stellar panel of experts from Nomi Health, the Michigan Association of Health Plans, Michigan State University, and Sympl Benefits. Register to join the free webcast here: https://lnkd.in/gu4Yx6rm

With GLP-1 medications projected to become the costliest drug category within three years, employers face a challenge. How can they support employee health while managing costs? Our Trends in Spend analysis provides insights into utilization trends and cost drivers, helping employers make informed decisions about their health plans. Discover strategies for balancing health and costs:?https://lnkd.in/gR4fgZKc

We had a fantastic time at the Medicaid Enterprise Systems Community event in Louisville, KY, exchanging ideas about Medicaid systems —?and the health policies impacted by those systems. ? Here's our team at the event (L-R): Anna Volk, Makae Wright, Colleen Rooney?and Alexander Bueno.

Since acquiring Artemis in 2022, Nomi Health has expanded to offer networks, pharmacy services (CerpassRx), healthcare financial services, and integrated care programs. Now, with Betsy McVay leading Artemis by Nomi Health, we're enhancing these services with robust data capabilities. Learn about our comprehensive approach: https://lnkd.in/giH9nawZ